Bernstein Cuts PT on Smith & Nephew plc (SNN)
Key takeaways
- Bernstein Cuts PT on Smith & Nephew plc (SNN) Noor Ul Ain Rehman Tue, May 26, 2026 at 7:08 PM GMT+7 1 min read SNN Smith & Nephew plc (NYSE:SNN) is one of the best robotic surgery stocks to buy.
- Smith & Nephew plc (NYSE:SNN) also received a rating update from Canaccord the same day, with the firm cutting the price target on the stock to $30 from $32 and maintaining a Hold rating on the shares.
- Smith & Nephew plc (NYSE:SNN) develops, manufactures, markets, and sells medical devices.
Bernstein Cuts PT on Smith & Nephew plc (SNN) Noor Ul Ain Rehman Tue, May 26, 2026 at 7:08 PM GMT+7 1 min read SNN Smith & Nephew plc (NYSE:SNN) is one of the best robotic surgery stocks to buy. Bernstein cut the price target on Smith & Nephew plc (NYSE:SNN) to $31.85 from $36.20 on May 11, maintaining a Market Perform rating on the shares. The rating update came after the company provided a fiscal Q1 trading update on May 6, with the firm noting that reported sales were up 3.1% organically, missing consensus growth of 3.8%.
Smith & Nephew plc (NYSE:SNN) also received a rating update from Canaccord the same day, with the firm cutting the price target on the stock to $30 from $32 and maintaining a Hold rating on the shares. The firm updated its model on the stock after its fiscal Q1 results to take into account comp-group compression.
In its financial results for fiscal Q1 2026, Smith & Nephew plc (NYSE:SNN) reported revenue of $1,501 million, with underlying revenue growth of 3.1%, and reported revenue growth of 6.6%, which included a 350bps foreign exchange tailwind.